# High-Dose vs Standard-Dose GLP-1 Before Neck Fusion (ACDF) Surgery | This GLP A matched study of 921 patients per group found high-dose GLP-1 therapy before neck fusion surgery produced no more complications, readmissions or failed fusions. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-neck-fusion-high-dose Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # High-Dose vs Standard-Dose GLP-1 Before Neck Fusion (ACDF) Surgery Neck fusion patients on a high-dose GLP-1 did no worse than those on a standard dose, across nine outcomes and two years. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 High dose above, standard dose below — no p-value under 0.2 · readmitted · 11.4 / 10.0% · ED visit · 11.4 / 12.3% · complication · 9.6 / 8.9% · failed fusion · 4.0 / 3.8% · 921 matched patients per group, neck fusion surgery. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Patients having neck fusion surgery were split by whether their GLP-1 prescription was a high or standard dose. - After matching, 921 remained in each group, drawn from 112,065 screened across three comparisons. - Nothing differed: readmission, emergency visits, complications, swallowing problems, opioid use, failed fusion. - Both dose groups had less failed fusion than matched non-users, with no extra gain from the higher dose. - No funding was received and the authors declare no study-specific conflicts. The question this study asks is one a buyer has to answer every time a titration schedule moves up a rung, and the answer here is that a stronger prescription did not change anything the surgeons measured — which is not the same as saying [a higher dose adds nothing](https://thisglp.com/research/is-a-higher-semaglutide-dose-worth-it), since the outcomes counted here are surgical rather than metabolic. ## What was compared Anterior cervical discectomy and fusion is the operation that removes a damaged disc in the neck and fuses the two vertebrae together, and it has a well-known failure mode: the bones do not knit, which is called pseudarthrosis and often means a second operation. Adults who had one were pulled from a research network and sorted by the strength of the GLP-1 prescription recorded for them between one year and one week before surgery. [\[1\]](https://thisglp.com/research/glp1-neck-fusion-high-dose#ref-1) Three pairwise comparisons were run, covering 112,065 patients in total. The one the paper treats as primary sets high dose against standard dose, and after matching it holds 921 people on each side. ## What it found Readmission within ninety days ran 11.4% against 10.0%, p = 0.327. Emergency visits 11.4% against 12.3%, p = 0.564. Composite medical complications 9.6% against 8.9%, p = 0.629. Difficulty swallowing, a characteristic complication of this operation, ran 10.6% against 11.2%, p = 0.709. Opioid exposure was 85.2% against 83.1%, p = 0.202, and out at 180 to 720 days failed fusion ran 4.0% against 3.8%, p = 0.822, with second-stage posterior fusion at 3.0% against 3.7%, p = 0.398. There is no result in that list that a reader could mistake for a signal. A null on 921 people A clean set of non-findings across nine outcomes is genuinely reassuring about large effects and says very little about small ones, because 921 patients per arm can only rule out differences of a certain size — and none of these p-values comes close enough to the threshold to look like a study that nearly found something. Read it as an absence of any obvious dose penalty, which is what the authors claim, rather than as [a demonstration that no difference exists](https://thisglp.com/research/does-a-glp1-affect-surgery-outcomes). ## The comparison against non-users Both dose groups had lower failed-fusion rates than matched patients taking no GLP-1 at all, and the higher dose added nothing further on top of that. That second comparison is the weaker of the two, because people on a GLP-1 and people on nothing differ in ways a database records imperfectly, and this section has already watched [three significant differences vanish](https://thisglp.com/research/glp1-shoulder-surgery-adjustment) when that gap was closed properly. The dose comparison does not have that problem, since everyone in it was taking the same drug. ## Why the dose field matters here This study could sort patients by dose because a prescription record carries a strength. The dose is a field somebody wrote down, and the analysis exists because of it. Most sellers publish a monthly figure and say nothing about what happens to it as the dose climbs, which is the gap [the dose-ladder tool](https://thisglp.com/tools/published-dose-ladders) was built to count. Nothing in this paper is about pricing. It is a reminder that the distinction between a starting dose and a maintenance dose is real enough for researchers to build a study on, and vague enough on a checkout page to be unanswerable. ## Frequently asked Is a higher GLP-1 dose riskier before surgery? Not in this study. Across readmission, emergency visits, complications, swallowing problems, opioid use and failed fusion, no outcome differed between high-dose and standard-dose patients. How many people were compared? 921 in each arm of the dose comparison, matched one to one, out of 112,065 patients screened across three comparisons. Did being on a GLP-1 at all help the fusion? Both dose groups had lower failed-fusion rates than matched non-users, but that comparison is between people on the drug and people not on it, which database matching handles poorly. Who paid for the study? Nobody. The authors report no funding and no study-specific conflicts of interest. ## Sources 1. \[1\] Stirpe C, et al. (2026). Impact of GLP-1 Dose Intensity on Perioperative and Long-Term Fusion Outcomes Following ACDF The Spine Journal. [PMID 42705550](https://pubmed.ncbi.nlm.nih.gov/42705550/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes)